Polypeptide with anti-microbial activity that is produced by strains of Bacillus licheniformis or Bacillus subtilis. Indicated for topical use (high nephrotoxicity with systemic use) Not absorbed through skin, mucosa or intestinal tract. When orally taken it is destroyed by the gut with no pass into the blood stream. Preferably, avoid it on the breast or clear it out before nursing. Avoid use of creams, gels and other topical medication containing paraffin (petroleum-derived mineral oil) in order to avoid the risk of absorption by the child. The WHO Model List of Essential Medicines 2002 rates it as compatible with breastfeeding.Safe
CAS Number: 1404-04-2
Aminoglycoside antibiotic which is used in creams, eye drops, and otologic preparations for topical use, and, also orally used for intestinal disinfection. At latest update, relevant published data on excretion in the breast milk were not found. Like other aminoglycoside antibiotics, Neomycin is not absorbed by the gut. Absorption from other sources like skin, nose, ear and eye mucosa by means of topically used preparations (creams, drops, etc.) is very poor which causes excretion into breast milk in significant amount, unlikely. Do not apply creams, gels and other products that would contain paraffin (mineral oil) to avoid absorption by the infant since it is a hydrocarbon-derived substance. In case of use of Neomycin on the nipple, let it be done after the feed and wipe it out any excess of cream before the next feed. Be aware of false negative results of microbial cultures done from samples of febrile infants whose mothers are treated with antibiotics. Also, due to imbalance of intestinal flora a diarrheal disease can occur in the breastfed infant. List of Essential Medicines by WHO 2002: compatible with breastfeeding.Safe
CAS Number: 1405-20-5
Antibiotic drug that is usual topically used (Dermatology, ENT and Ophthalmology) At latest update no published data on excretion into breast milk were found. The small dose and low absorption to the plasma in a majority of preparations that are topically used on the eye, ear or skin make a significant excretion into the milk unlikely. Its high molecular weight makes less probable an excretion into breast milk in significant amount. Due to a poor oral bioavailability, appearance in the infant's plasma from ingested milk is regarded as nil or scanty, except in premature infants or during the immediate neonatal period who may show an increased intestinal absorption. Polymyxin E or Colistin with a very similar molecular structure is excreted into breast milk in non-significant amount. It is advisable to avoid the application of creams, gels and other products for local use that would contain paraffin (mineral oil) to prevent absorption by the infant.
CAS Number: 8001-54-5
Topical maternal application of benzalkonium chloride or benzethonium chloride or their presence as a preservative in pharmaceuticals would not be expected to cause any adverse effects in breastfed infants.
CAS Number: 1405-87-4
Because it is poorly absorbed after topical application and oral ingestion, bacitracin is considered a low risk to the nursing infant. Only water-miscible cream or gel products should be applied to the breast because ointments may expose the infant to high levels of mineral paraffins via licking.
CAS Number: 1404-04-2
Although no information exists on the excretion of neomycin into milk, other aminoglycoside antibiotics are poorly excreted into breastmilk. Newborn infants apparently absorb small amounts of aminoglycosides, but serum levels are far below those attained when treating newborn infections and systemic effects of neomycin are unlikely. Older infants would be expected to absorb even less neomycin. Monitor the infant for possible effects on the gastrointestinal flora, such as diarrhea, candidiasis (e.g., thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis. Oral, topical, ophthalmic or otic neomycin should result in very low levels in breastmilk and present negligible risk to the infant, although topical application to the nipple may increase the risk of diarrhea in the infant. Only water-miscible cream or gel products should be applied to the breast because ointments may expose the infant to high levels of mineral paraffins via licking.
CAS Number: 1404-26-8
Because it is poorly absorbed after topical application, polymyxin B is considered a low risk to the nursing infant. Only water-miscible cream or gel products should be applied to the breast because ointments may expose the infant to high levels of mineral paraffins via licking.
As usage of Refill 2 | Benzalkonium Chloride, Bacitracin Zinc, Neomycin Sulfate, Polymyxin B Sulfate Kit is mostly safe while breastfeeding hence there should not be any concern. In case of any change in behavior or health of your baby you should inform your health care provider about usage of Refill 2 | Benzalkonium Chloride, Bacitracin Zinc, Neomycin Sulfate, Polymyxin B Sulfate Kit else no further action is required.
Definitely, Refill 2 | Benzalkonium Chloride, Bacitracin Zinc, Neomycin Sulfate, Polymyxin B Sulfate Kit is safe in lactation for baby. No wonder your doctor has recommended it.
No extra baby monitoring required while mother is using Refill 2 | Benzalkonium Chloride, Bacitracin Zinc, Neomycin Sulfate, Polymyxin B Sulfate Kit
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week